VKTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VKTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Viking Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Viking Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Viking Therapeutics did not have earnings to cover the interest expense. As of today, Viking Therapeutics's Altman Z-Score is 0.00.
For the Biotechnology subindustry, Viking Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Viking Therapeutics's Interest Expense for the months ended in Mar. 2024 was $-0.03 Mil. Its Operating Income for the months ended in Mar. 2024 was $-34.07 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.85 Mil.
Viking Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
Viking Therapeutics did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Viking Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.329 | + | 0.852) | / | 0 | |
= | N/A |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Viking Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics (NAS:VKTX) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Viking Therapeutics has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.
Thank you for viewing the detailed overview of Viking Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarah Kathryn Rouan | director | 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017 |
Greg Zante | officer: Chief Financial Officer | C/O SANGAMO BIOSCIENCES, INC STE-A-100, POINT RICHMOND TECH, 501 CANAL BLVD,, RICHMOND CA 94804 |
Rowland Charles A Jr | director | 3338 LANCASHIRE RD, FURLONG PA 18925 |
Lawson Macartney | director | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Brian Lian | director, officer: President & CEO | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
Marianna Mancini | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, STE 250, SAN DIEGO CA 92130 |
Matthew W Foehr | director | 11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037 |
Ligand Pharmaceuticals Inc | 10 percent owner | 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO CA 92121 |
Hiroko Masamune | officer: Chief Development Officer | C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Michael Morneau | officer: Chief Financial Officer | C/O TRIUS THERAPEUTICS, INC., 6410 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
J Matthew Singleton | director | 286 STANWICH ROAD, GREENWICH CT 06830 |
Stephen W Webster | director | C/O OPTIMER PHARMACEUTICALS, INC, 101 HUDSON STREET, SAN DIEGO CA 07302 |
Rochelle Hanley | officer: Chief Medical Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
Michael Dinerman | officer: Chief Operating Officer | C/O VIKING THERAPEUTICS, INC., 11119 NORTH TORREY PINES ROAD, SUITE 50, SAN DIEGO CA 92037 |
From GuruFocus
By PRNewswire • 10-18-2023
By PRNewswire PRNewswire • 02-01-2023
By PRNewswire • 09-07-2023
By PRNewswire • 12-04-2023
By GuruFocus Research • 01-05-2024
By PRNewswire • 11-02-2023
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 03-28-2023
By PRNewswire PRNewswire • 03-29-2023
By GuruFocus Research • 01-20-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.